FGFR2 Is Amplified in the NCI-H716 Colorectal Cancer Cell Line and Is Required for Growth and Survival

Open Access

Peer-reviewed

Research Article

Anjili Mathur,

Affiliation Merck Research Labs, Boston, Massachusetts, United States of America
⨯
Christopher Ware,

Affiliation Merck Research Labs, Boston, Massachusetts, United States of America
⨯
Lenora Davis,

Affiliation Merck Research Labs, Boston, Massachusetts, United States of America
⨯
Adi Gazdar,

Affiliation Hamon Center for Therapeutic Oncology, University of Texas Southwestern, Dallas, Texas, United States of America
⨯
Bo-Sheng Pan,

Affiliation Merck Research Labs, Boston, Massachusetts, United States of America
⨯
Bart Lutterbach

* E-mail: lutterba@gmail.com

Affiliation Merck Research Labs, Boston, Massachusetts, United States of America
⨯

Reader Comments (0)

Colorectal cancer
Is the Subject Area "Colorectal cancer" applicable to this article?

Thanks for your feedback.
Gastric cancer
Is the Subject Area "Gastric cancer" applicable to this article?

Thanks for your feedback.
Cancer treatment
Is the Subject Area "Cancer treatment" applicable to this article?

Thanks for your feedback.
Phosphorylation
Is the Subject Area "Phosphorylation" applicable to this article?

Thanks for your feedback.
Signal amplification
Is the Subject Area "Signal amplification" applicable to this article?

Thanks for your feedback.
Signal inhibition
Is the Subject Area "Signal inhibition" applicable to this article?

Thanks for your feedback.
Ascites
Is the Subject Area "Ascites" applicable to this article?

Thanks for your feedback.
Breast cancer
Is the Subject Area "Breast cancer" applicable to this article?

Thanks for your feedback.